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Precision genomic alterations largely rely on homology directed repair (HDR),
but targeting without homology using the non-homologous end-joining
(NHEJ) pathway has gained attention as a promising alternative. Previous
studies demonstrated precise insertions formed by the ligation of donor
DNA into a targeted genomic double-strand break in both dividing and
non-dividing cells. Here, we demonstrate the use of NHEJ repair to replace
genomic segmentswith donor sequences; we name thismethod ‘Replace’ edit-
ing (Rational end-joining protocol delivering a targeted sequence exchange).
Using CRISPR/Cas9, we create two genomic breaks and ligate a donor
sequence in-between. This exchange of a genomic for a donor sequence uses
neither microhomology nor homology arms. We target four loci in cell lines
and show successful exchange of exons in 16–54% of human cells. Using
linear amplification methods and deep sequencing, we quantify the diversity
of outcomes following Replace editing and profile the ligated interfaces. The
ability to replace exons or other genomic sequences in cells not efficiently
modified by HDR holds promise for both basic research and medicine.1. Introduction
RNA-guided nucleases [1–3] have rapidly become foundational tools in facilitat-
ing genomicmanipulations [4,5]. These nucleases target specific genomic loci and
form a double-strand break (DSB). DNA repair processes are then leveraged to
produce the desired outcome of the gene editing. Conventionally, specific geno-
mic changes are made using homology directed repair (HDR) [6,7] with
exogenously introduced DNA containing flanking sequences homologous to
the targeted locus. One limitation of HDR-mediated genome editing is its restric-
tion to the S/G2 phase, reducing or abolishing efficacy in slowly or non-dividing
cells [8]. HDR, when used for gene editing, can be precise, but recent reports
demonstrate greater error than often assumed, as incomplete or extraneous por-
tions of the delivery vector can be copied into the genome [9–13]. On the other
hand, the canonical non-homologous end-joining (NHEJ) pathway is traditionally
viewed as error prone and relegated to disrupting gene function by inducing
small insertions and deletions (InDels) during DSB repair. However, the high-
fidelity aspects of NHEJ repair are often underappreciated as mutant InDels are
easily observed, whereas non-mutagenic repair is indistinguishable from the
original allele [14]. Furthermore, non-mutagenic repair by NHEJ reforms the
Cas9 target site allowing for continued DSB formation. This may result in a
final genomic population containing majority InDels despite NHEJ repair being
predominately error-free.
Recently, increasing awareness of the fidelity and efficiency of NHEJ repair
has led to the development ofmethods to produce genomic deletions and exogen-
ous sequence insertions using this pathway. AsNHEJ is highly active in all phases




2Targeted deletions are produced by forming two DSBs with
loss of the intervening sequence during repair. The ubiquitous
nature of the NHEJ pathway allows for deletions in zygotes, as
well as in adult tissue such as in vivo exon deletion in a mouse
muscular dystrophy model [16,18]. Additionally, exogenously
introduced dsDNA donor sequences can efficiently ligate into
a single DSB by NHEJ (herein referred to as Insert targeting)
[15,17,19–26]. With the NHEJ pathway conserved broadly,
Insert targeting has been shown in plants [25], fish [19], cell
lines [20–24,26], nondividing neurons and in vivomouse tissues
[15,17]. The ability to effectively integrate DNA across cell
types has been used to tag genes with fluorophores
[15,24,26], identify off-target CRISPR cleavage sites [27] and
as a strategy for gene therapy by inserting functional coding
sequences upstream of a disease causing exon [17].
Leveraging NHEJ repair to create large deletions and insert
exogenous DNA posits the possibility of NHEJ-based sequence
replacement; two DSBs are produced and a donor sequence
without homology is ligated between the two breaks. This
approach would enable the replacement of defective exons or
regulatory sequences in a wide range of resting or dividing
cells. NHEJ-based replacement has been demonstrated in
plants, where HDR is often infeasible [28,29]. In order for
NHEJ-based replacement to be considered a viable approach
in human cells, demonstration of its efficiency and a thorough
understanding of the editing outcomes is required. Here, we
demonstrate efficient replacement of genomic sequences and
exons with a donor sequence in human cells using NHEJ
repair; we call this method Replace (Rational end-joining
protocol delivering a targeted sequence exchange). Analysis
of single-cell-derived clones provides conclusive evidence of
Replace editing and efficiency.We further introduce sequencing
pipelines for the precise quantification of the structural variants
produced during Replace targeting and the InDels at the ligated
interfaces. Together, our results and analysis strategies lay the
groundwork for future applications of NHEJ-based Replace
editing in gene therapy and research.2. Results
Replace targeting (figure 1a) aims to exchange a genomic
sequence with a double-stranded donor sequence without
the use of homology. In this strategy, undesired products
such as deletions or inverted donor sequences reform the
Cas9 gRNA target sites and can be further targeted by
Cas9, while the desired integration is captured. For initial
validation, we used a fluorescence-based reporter system
(figure 1b). The synthetic reporter system was created and
integrated into two AAVS1 loci in a HeLa cell line.
The reporter system contains a CAG promoter upstream of
a BFP fluorophore. The BFP prevents the expression of a
downstream Venus-pA. The cells initially are BFP+. Replace
targeting exchanges the BFP cassette with a mCherry
donor. Reporter HeLa cells were lipofected to deliver the
donor sequence and Cas9 plasmid containing a puromycin
resistance gene. Cells were selected for 48 h to ensure con-
struct delivery and analysed after two weeks. Replacement
targeting cleaved both sides of the BFP-pA cassette, with
the excised sequence exchanged with the linearized mCherry
donor sequence. Correct ligation of mCherry resulted in the
loci expressing only mCherry. Deletion of the BFP cassette
without replacement resulted in expression of thedownstream Venus. Some alleles lost expression due to
mutations or incorrect donor ligation.
Replace targeting of the reporter locus resulted in 34%
mCherry+ cells (figure 1c). We compared the effect of deliver-
ing donor sequences within a plasmid or in the form of
minicircles as a previous report showed minicircles to increase
Insert efficiency [17] (figure 1d). Minicircles are minimal plas-
mids and contain only the donor sequence and require only a
single Cas9 DSB for linearization, whereas plasmids require
two DSBs to excise the donor. Donor sequences delivered as
minicircles resulted in a sixfold increase in cells with mCherry
expression compared to plasmid delivery. We therefore used
minicircles for Replace targeting in the remainder of this
work. To address if mCherry expression was driven in part
by off-target integration of the donor sequence, we Replace tar-
geted, in an otherwise identical manner, wild-type HeLa cells.
As these cells do not contain the AAVS1 integrated promoter
and target site, only off-target integration could result in
mCherry expression (figure 1d). Wild-type HeLa cells
showed no mCherry expression indicating that the 34%
mCherry+ cells in our original experiment are the result of cor-
rect integration at the target loci. mCherry+ cells were single-
cell sorted, expanded and genotyped to check for correct
sequence replacement. Twenty-four out of 25 analysed clones
(i.e. 32% of all cells) contained the anticipated exchange of
BFP with mCherry, while one clone contained an allele with
mCherry insertion upstream of BFP (figure 1e). AsHeLa repor-
ter cells contained two copies of the reporter locus, we quantify
the frequency of homozygous knock-in by simultaneously
transfecting two donor sequences (mCherry and miRFP670)
(electronic supplementary material, figure S1). By measuring
the mCherry+, RFP+ and dual-positive populations, we calcu-
lated an average of 5% homozygous knock-in. Taken
together, Replace targeting in our reporter system occurs as a
major outcome, with a successful sequence exchange of at
least one allele in 32% of cells.
During the ligation of the donor sequence into the
genome, InDels may occur at the interface. To quantify
short InDels, the gDNA of targeted and unsorted HeLa
reporter cells was PCR amplified using primers flanking the
ligated interface. The deconvolution of the Sanger traces of
these amplicons provides an InDel estimate of the bulk popu-
lation of Replace targeted cells (figure 1f ). This analysis
shows that short resection occurs in a minor (less than 16%)
fraction of these small amplicons. The majority contained
no InDel or a small, non-random insertion. Sanger sequen-
cing of cloned individual alleles supports the bulk analysis
(electronic supplementary material, figure S2A). The one or
two nucleotide insertions were striking in that they matched
the protospacer sequence downstream of the break site. It is
known that SpyCas9 does not always form a canonical
blunt end break three nucleotides downstream of the PAM,
but can, at some frequency, form a staggered cut [30–33].
These non-random insertion InDels are probably caused by
NHEJ acting on a Cas9-formed staggered cut (electronic sup-
plementary material, figure S3). In this model, the sticky end
cutting causes the PAM side of the break to contain extra
nucleotides. These overhangs are filled during repair and
appear as insertions when the two PAM sides are ligated in
Replace targeting (figure 1f ). This produces insertions in
the interfaces of the PAM sides and not in ligated interfaces
of two Protospacer sides of the break (electronic supplemen-






Figure 1. Replace targeting using HeLa reporter cells. (a) Overview of replace targeting concept: correct donor integration disrupts the Cas9 targeting sequence and is
captured, while undesired products (deletion or inverted integrants) reform the gRNA target and can be further cut. (b) HeLa cells containing a fluorescent reporter
system integrated into two AAVS1 loci. Targeting used gRNA-1 shown in (a) with two identical sites flanking BFP. Lipofection of Cas9-2A-puro/gRNA-1 and the donor
sequence was followed by 48 h puromycin selection to ensure complete delivery. (c) Results of Replace targeting with a minicircle donor measured by FACS. BFP, original
allele; Venus, deletion; mCherry, donor integration; colourless, allelic damage. Total sums to greater than 100% as cells can express two fluorophores. (d ) Replace
targeting using minicircles and plasmid sequence donors. WT cells are HeLa cells without the integrated reporter system. WT targeted identically. p-value was calculated
using Student’s t-test (****p-value <0.0001). (e) Single-cell sorted Replace targeted, mCherry+ cells were expanded and genotyped. Correct exchange of BFP by
mCherry (Replacement) and mCherry integration flanking the BFP (Insertion) were both measured. ( f ) InDel frequencies at the interface of the integrated donor





To test Replace targeting of an endogenous gene, we tar-
geted three ubiquitously expressed loci in K562 cells:
Polymerase Beta (POLB) exon 5, CCNA1 exon 2 and LMNA
exon 2. We replaced exons with a splice acceptor-2A-
mCherry-pA donor sequence (figure 2a,b). Replace targeting
resulted in reporter expression stable over weeks (figure 2c).
Genotyping of mCherry+ single-cell derived colonies showed
mCherry integration into the targeted locus in 100%of colonies.
Correct replacement ranged from 60% to 93% of the colonies,
but in some cells, the donor mCherry sequence inserted next
to the original exon without replacing it (figure 2d). Sangersequencing of the genome–donor sequence interface of individ-
ual PCR amplified alleles showed modest InDel formation in
the correctly exchanged alleles (figure 2e; electronic sup-
plementary material, figure S2). Replicate targeting
experiments gave an average of 58%, 39% and 19% mCherry+
cells forPOLB exon 5,CCNA1 exon 2 andLMNA exon 2 respect-
ively (figure 2f ). All three targeted loci are triploid in K562 [34],
assuming independence in the editing events, we can estimate
the corresponding diploid cells would measure 44%, 28% and
13% mCherry+ for POLB, CCNA1 and LMNA, respectively.







Figure 2. Exon Replace editing in K562 cells. (a) Replacement of POLB Exon 5, CCNA Exon 2 or LMNA Exon 2 with a cherry reporter including a splice acceptor (SA),
T2A self-cleaving peptide and a polyadenylation site (bpA). (b) K562 cells cotransfected with Cas9-2A-puro/guides plasmid and mCherry Minicircles were puromycin
selected for 48 h and followed by FACS analysis over five weeks. (c) mCherry+ count of transfected cell cultures was measured weekly by FACS. (d ) Colonies of
mCherry+ single cells were expanded and genotyped to check and quantify replacement of the exon with the donor sequence. (e) Sanger sequencing of amplicons





estimate of 54% of POLB, 23% of CCNA1 and 16% of LMNA
Replace targeted cells with successful replacement in K562.
It is known that large-scale deletions may follow a single
Cas9-driven DSB [35], and Replace targeting further compli-
cates analysis due to the structural variants formed by the
two genomic breaks and donor sequence integration. In
order to quantify large deletions and the directionality of
donor integration, we performed long-read deep-sequencingon amplicons of the targeted loci from unsorted Replace tar-
geted HeLa cells and Replace targeted K562 cells (figure 3).
We used primers 800–2000 bp away from the DSBs to gener-
ate long amplicons that were sequenced with PacBio
technology. A bioinformatics pipeline was built to analyse
large deletion and structural outcome frequencies (figure 3a)
(electronic supplementary material, figure S4). While a donor





Figure 3. Long-read deep sequencing of Replace targeted cells. (a) Unsorted HeLa reporter cells or K562 POLB exon 5 targeted cells. Loci were amplified using the primers
more than 800 bp from the Cas9 breaksites; amplicons were sequenced using PacBio technology (b). Directionality of structural variants formed after Replace targeting.
BFP/exon 5 pie charts are alleles containing the original targeted allele and no donor. mCherry pie charts show alleles where mCherry replaced targeted sequence.
Insertion is both donor sequence and targeted sequence in the loci. (c) Forty representative alignments of three major type of alleles: allele with original sequence,
sequence exchanged with mCherry, or a deletion allele. (d ) An average deletion profile of reads in which Replace editing using the mCherry donor was successful.








Figure 4. Linear amplification analysis of POLB exon 5; quantifying on-target Replace outcomes and mapping donor sequence integration. (a) Replace overview
showing primer binding used for linear amplification. Unsorted gDNA was amplified with primer 1 or primer 2 and a universal primer, sequenced using Illumina
technology, and analysed. (b) Pipeline 1 analysis of Uditas prepared samples quantifies outcomes at the targeted site with the corresponding InDels quantification.
(c) Pipeline 2 analysis of UDiTaS prepared samples shows mCherry integration with an overall quantification of donor sequence integration. (d ) Donor sequence
integration mapped across the genome with read counts plotted logarithmically. Chromosomes with no integration sites were removed. Top 10 predicted Cas9 off-





in both directions, inspired by thework of Suzuki et al. [17], we
designed a preferred orientation into our donor sequencewith-
out the use of homology (electronic supplementary material,
figure S5). When the donor integrated in the undesired direc-
tion the ligated interface reform the Cas9 target site, whereas
the desired orientation is unable to be further cut. Long-read
deep sequencing measured the desired orientation of mCherry
in 79% of reads where BFP was replaced in HeLa and 89% of
alleles with POLB exon 5 replacement in K562 (figure 3b).
Even alleles containing unintended donor insertion of
mCherry into a DSB flanking the targeted sequence integrated
preferentially in the designed orientation.
Alignment of the reads showed alleles with large-scale
deletions (greater than 500 bp) occurred (figure 3c). Notably,
individual reads showed that large-scale resection was fre-
quently asymmetric with one side of the break undergoing
dramatically larger resection. Viewing the frequency of a del-
etion at each base along the amplicon creates an averaged
deletion profile and shows that the majority of loci experi-
enced small-scale resection (figure 3d ). Specifically, insuccessfully Replace targeted alleles, deletion mutations at
the ligated junctions was smaller than 30 bp in greater than
90% of HeLa reporter reads, and smaller than 30 bp
in greater than 95% of the POLB exon 5 reads. The ligated
interface containing the protospacers were InDel-free in
79% of the correctly targeted reads of the HeLa reporter
(electronic supplementary material, S1) and 63% InDel-free
in the reads of the correctly targeted POLB K562 alleles, as
measured by collapsing the long-read data (electronic
supplementary material, S2).
Linear PCR methods requiring only one gene-specific
primer, such as UDiTaS [36] and LAM-HTGTS [37], offer
more complete and quantitative measurements of DNA
repair outcomes following a DSB. A gene-specific primer
binds upstream of the targeted break site and a universal
primer binding sequence is integrated downstream. Sub-
sequently, the PCR amplifies the region across the break
regardless of the structural variant, deletion size or transloca-
tion (figure 4a; electronic supplementary material, figure S4C,




7pipeline for CRISPR analysis. We modified this pipeline to
extend the capabilities for Replace targeting with two pipe-
lines (electronic supplementary material, figure S4E,F).
Pipeline 1 closely follows the published UDiTaS pipeline; it
aligns reads to the in silico reconstructed expected outcomes,
performs InDel analysis and quantifies these measurements.
The results of Pipeline 1 showed that at the targeted POLB
locus donor sequence integrated in the preferred orientation
at a 5 : 1 ratio to an inverted orientation (figure 4a,b). At
39% of all POLB alleles, the integration of the donor sequence
in the desired orientation is the single most frequent outcome
measured. Strikingly, more than one-third of these donors
were integrated without an InDel formed at the ligated inter-
face. This highlights both the efficiency and fidelity of
Replace targeting for exon replacement.
As exogenously introduced DNA is known to integrate
randomly into the genome [38], we developed Pipeline 2 to
quantify and map the integration location of the donor
sequence (electronic supplementary material, figure S4F).
Using a primer that binds the donor sequence and points
towards the ligated interface,we generated amplicons that con-
tain the flanking genomic sequence. These amplicons were
Illumina sequenced, and the genomic sequences beyond the
end of the donor sequence were aligned to the human
genome (figure 4c; electronic supplementary material, figures
S4C and S5). Sequence alignment showed 55% on-target inte-
gration into the POLB locus. Thirty-four per cent of all
measured donor sequences had formed concatenations; it
remains to be determined where these concatenated sequences
are integrating within the genome, but concatenation of
exogenous dsDNA itself is a known phenomenon [9,39–42].
The donor sequences were shown to be integrated into the
genome at more than 28 loci (figure 4d). Interestingly, none
of the off-target integrationmapped to any of the 293 predicted
[43] SpyCas9 off-target sites.3. Discussion
This work demonstrates that NHEJ-based genomic sequence
exchanges are feasible and efficient in human cells. In the
four loci tested, replacement was successful in 16–54% of
cells; in one case, the desired product was the major outcome.
We furthermore demonstrated targeted exon replacement via
NHEJ in three widely expressed human genes. Based on the
comprehensive analysis of our targeted alleles, we arrive at
three design principles to guide future Replace work.
The first design aspect ensures the correct orientation of
the donor sequence in the genome. Linearizing the donor
sequence with the same gRNA that cuts the target locus
allows incorrectly ligated donors to be re-cut and excised
(electronic supplementary material, figure S6). It is crucial
to add a gRNA targeting the sequence formed during a del-
etion. This gRNA re-opens alleles that form a deletion and
also excises out incorrectly ligated donor sequences. The
minimal requirement for this design is two gRNAs (electronic
supplementary material, figure S6B,C). Long-read sequen-
cing confirmed 89% of the donor sequences integrated in
the designed orientation after POLB exon 5 Replace editing.
The second design principle is to avoid gRNAs that are
involved in non-canonical SpyCas9 sticky end cutting. The fre-
quency of ‘InDel free’ ligated interfaces measured in this work
supports the idea that NHEJ repair is often not mutagenic [14].We believe breaks introduced by Cas9 are often re-ligated to
reform the original sequence, which can then be cleaved
again—forming a break ligation cycle. This cycle continues
until the Cas9 is no longer active or the target site forms an
InDel during repair and disrupts Cas9 binding. For efficient
Replace targeting, prolongation of this cycle provides more
time to acquire and ligate the donor sequence in the correct
orientation. InDel mutations remove alleles from the ligation
cycle and thus decrease efficiency. One avoidable driver of
InDel formation is non-canonical SpyCas9 cutting in which a
staggered cut is formed [30–33]. The staggered cut is filled in
and then ligated, duplicating the staggered nucleotide(s). The
resulting small insertions are easily identifiable as they match
the nucleotides of the protospacer sequence beyond the
expected break site (electronic supplementary material, figure
S3). Data from large gRNA screens suggest this mechanism
as the predominant driver of +1 insertions [44]. The non-cano-
nical cutting of SpyCas9 may be sequence or loci-dependent.
Empirical testing of a gRNA by measuring InDel outcomes
[45], therefore, allows us to avoid sites that incur staggered cuts.
The third concept is to design sacrificial sequences around
the ligated regions to buffer possible resection and sequence
deletions. While the overall rate of InDels and large-scale del-
etion is low, detrimental effects can be further reduced.
During exon Replace targeting, we cut in intronic regions out-
side the splice site as short intronic InDels are less likely to be
detrimental to gene function. Long-range deep sequencing
showed that in our systems, the vast majority of the InDels
are less than 30 bp long. Considering this, we recommend a
sacrificial buffer 30 bp or greater be included on the flanks of
the Replace construct to protect the splicing donor/acceptor
and coding sequence.We currently useminicircles but also rec-
ommend such buffers on AAV delivered donor sequences too.
NHEJ-based sequence replacement has previously been
explored using PCR fragments as donor sequence [46]. How-
ever, the genetic analysis in that study was not sufficient to
distinguish successful replacement from other possible editing
outcomes, such as unintended Insert targeting, structural
rearrangements and off-target integration. Therefore, it
remains to be confirmed and quantified in future work, if
Replace editing with PCR donor templates is a viable strategy.
Measuring the outcomes of Replace targeting is compli-
cated by the various structural rearrangements formed.
Additionally, a growing body of literature documents complex
outcomes following even simple Cas9-formedDSBs. These can
include large-scale resection [35], chromosomal fusions [36],
mis-spliced mRNA [47] and unintended vector integration
into the break site [16]. In working towards a full understand-
ing of the outcomes of Replace targeting, we developed
multiple deep sequencing pipelines. Long-read sequencing of
PCR amplicons of the targeted loci proved useful in illuminat-
ing resection profiles and gives insight into the orientation of
the structural variants produced. However, samples prepared
for long-read sequencing used two gene-specific primers and
so suffered fromPCRbias, over-representing the shorter ampli-
cons, making quantitative comparisons of alleles of different
lengths impossible. Traditional two primer PCR also requires
both intact binding sites, and unable to amplify more complex
repair products. To address these shortcomings, we turned to
single primer amplification methods such as UDiTaS and
LAM for quantitative analysis, as they amplify all outcomes
approximately equally and measure more complex repair




8in POLB editing to be 26% of all alleles and only 16% of alleles
maintained their wild-type allele. A total of 39%of alleles show
correct integration of the donor, and the restwould not produce
functional protein (structural inversions or deletions). This
ability to measure knock-in and knock-out rates concurrently
is helpful in understanding the function at the cellular level.
In contrast with other studies measuring repair outcomes of
a Cas9 DSB [36], we did not detect chromosomal fusions at
our break points. However, this may be due to our analysis
time point three weeks post-targeting, where alleles could
have been selected out of the population. Beyond the utility
for quantitative measurements on-target, these single-gene
primer protocols are powerful for measuring unintended inte-
gration of introduced DNA sequences. For example, in treating
a mouse model of muscular dystrophy, linear amplification
measurements showed the therapeutic AAV unintentionally
integrated into the Cas9 break site and throughout the
genome [16]. These unintended integration of AAV in human
cells may have a carcinogenic potential [48]. Others have
recently demonstrated high rates of unintended on- and off-
target integration of AAVs using single primer amplification
[49]. Replace donor sequences have the potential to integrate
into the target site or off-target into the genome. To our knowl-
edge, this is the first work to map and quantify off-target
integration or concatenation of donor sequences following
NHEJ Insert or Replace targeting. Using a primer on the
donor sequence, we detected substantial off-target integration
of the donor. Strikingly, none of these off-target integration loci
werewithin 5000 bases of the top 293 predicted Cas9 off-target
sites. Rates of off-target integration may be similar for double-
strandedHDR templates, but to our knowledge, off-target inte-
gration mapping by linear amplification has not been done
after an HDR editing making comparison difficult. Single-
stranded donor templates are known to integrate off-target
less frequently [7,50], but off-target quantification has mainly
relied on integration of large fluorescent cassettes and could
benefit from using single primer amplification approaches.
There are currently over 3800 genes known to cause
monogenic diseases with mutations often spread across mul-
tiple exons. Gene editing holds great potential for the
treatment of such diseases, but reversing the genetic defects
in terminally differentiated or resting cells remains a major
challenge [51]. HDR is unable to target non-dividing cells
[8], but the NHEJ pathway is known to be preserved across
cells types and cycle [52]. NHEJ-based Insert targeting had
previously been shown efficient in a wide variety of non-
dividing and dividing cells in vivo and in vitro. The use of
such NHEJ Replace editing holds the most potential for thera-
pies looking to correct mutations in non-dividing cells by the
replacement of exons. However, it was not clear if the NHEJ
repair would allow for effective genetic replacement, but
instead result in majority deletions, inserts or InDels.
Additionally, the size variation between possible repair out-
comes (i.e. deletions, insertions, replacements) makes their
quantitative analysis challenging. In this work, we have
demonstrated that the kinetics and fidelity of the NHEJ path-
way allows for efficient replace targeting in human cells, and
that a thorough understanding of the edited population can
be achieved based on single primer PCRs, long PCRs and tai-
lored analysis pipelines. While many questions, such as
optimal donor delivery, remain to be addressed, our work
provides the foundation for future applications of Replace
editing for genome engineering.4. Material and methods
4.1. Data and methods availability
Sequencing data are available. Sequence Read Archive
(SRA) accession: PRJNA622521. Extended protocols are avail-
able at https://www.protocols.io/researchers/eric-danner/
publications. Plasmids were submitted to Addgene
(https://www.addgene.org/Ralf_Kuehn, #149344–#149354)
and a folder of annotated genebank (.gb) files is added as
electronic supplementary material, S1. All code used is
available on Github: https://github.com/ericdanner. This
includes scripts, Jupyter notebooks and Conda environments.4.2. DNA constructs
Cas9-2A-puro targeting plasmid is Addgene ID 62988 with F1
sequence removed. The AAVS1 targeting fluorescent reporter
system was modified from Addgene ID 60431. The neomycinR
sequence was modified to a more robust form [53]. The RTTA3
gene was replaced by a BFP-pA-Venus-pA where the BFP is
flanked by Rosa26 sequences constructed by Gibson Assembly.
Guide RNA target sequences were ligated into BbsI cleaved
plasmids using synthetic oligonucleotides (table 1). When
more than one guide was necessary, the plasmids were com-
bined using Gibson Assembly.
Minicircles are produced in engineered bacteria using ara-
binose-induced recombination to remove the plasmid
backbone [54,55]. The ZYCY10P32T E. coli strain and the mini-
circle backbone were purchased from System Bioscience. After
cloning in the sequence into the specific minicircle backbone,
the plasmid is transformed into the ZYCY strain. The 200 ml
culture was grown in TB media for 16 h. Then 200 µl of 20%
L-arabinose was added and adjusted to pH 7 and 200 ml LB
were added. The culture was then shaken at 32°C for 4 h to
induce minicircle formation and slow cell division. An endo-
toxin-free purification kit (Macherey Nagel) was used
following the protocol for low copy number plasmids. The
resulting product contained plasmid and gDNA contami-
nation. Restriction enzymes cutting the backbone and gDNA
were added for 2 h. Then the resulting fragmented DNA was
digested with PlasmidSafe DNase for 16 h (Epicure).4.3. Cell culture and targeting
HeLa cells were cultured in DMEM, 10% FBS, 1% Penicillin/
Streptomycin and passaged with trypsin every 3–4 days. To
generate the fluorescent reporter line, plasmid #208 was
cloned. Successful integration into the AAVS1 loci generated
neomycin resistance. Cells were selected with 0.6 mg ml−1
G418 for one week. Single cells were FACS sorted into a
96-well plate and expanded. Colonies were checked for cor-
rect integration by genotyping and a clone with inserts on
both alleles was expanded and used. Targeting of Reporter
HeLa: 50 000 cells were reverse-transfected with 1.5 µg of
Cas9_2A_puro/guide plasmid + 1.5 µg of MC or plasmid
complexed with Lipofectamine 3000. The next morning
1.5 µg ml−1 puromycin was added for 48 h. Cells were then
FACS analysed. mCherry+ cells were single cell sorted into
a 96-well plate and expanded for genotyping. For the HDR
targeting experiment, the guide RNA targeting the Insert
site was used together with the donor plasmid.
Table 1. Primer table.































K-565, a leukaemia cell line, were kept in IMDM, 10%
FBS, 1% penicillin/streptomycin and split every 3 days. For
targeting, cells were nucleofected using the Lonza 4D
strips. A total of 5 × 105 cells were resuspended in nucleofec-
tion buffer [56] with 1 µg Cas9/guide plasmid and 3 µg of
minicircle and nucleofected using program FF-120. The
following day puromycin (4 µg ml−1) was added for 48 h.
4.4. Genotyping
For single-cell clones or bulk sequencing, genomic DNA
(gDNA) was extracted by quick extract (Lucigen). PCR
amplification was performed with LongAmp Polymerase
(NEB) or PrimerStar GXL (Takara). Primer pairs flanking
the upstream cut site or downstream cut site were used.
Amplicons were verified by gel extraction and Sanger
sequencing. Amplicons from bulk sequencing were cloned
into the TOPO vector (Invitrogen) before Sanger sequencing.
The frequencyof homozygous andheterozygous integration
in HeLa cells was determined by knocking-in mCherry
and miRFP670 simultaneously. By measuring mCherry+,
miRFP670+ and double positive cells, the homozygous
knock-in could be calculated [7].
We used modified ICE analysis for deconvolution of
amplicon Sanger trace data derived from unsorted Replacetargeted cells [45]. The amplicons were made using a
primer on the donor sequence and a primer on the genomic
sequence flanking the ligated site. The amplicon was cloned
into the TOPO vector and individual cloned alleles were
Sanger sequenced along with the mixed PCR product.
A cloned colony with Replace inserts without any InDels
was identified, and these Sanger trace data were used as
the ‘wild-type’ reference in ICE analysis.
4.5. Long-read deep sequencing and analysis
Bulk gDNA of targeted and control cells was amplified by
PrimeStar GXL for Polb targeting. The HeLa synthetic reporter
system required PCR with OneTaq (NEB) using the high GC
content additive to amplify through the very GC-rich CAG
sequence. Five-minute elongation steps were used to reduce
PCRbias.Ampliconswere cleanedbySPRIbeadsandquantified
by Qubit. The Libraries were pooled and prepared for PacBio
sequencing following company protocol. Data analysis was
done using ‘Pipeline Longread’. This pipeline uses custom
Python scripts for preprocessing andbins the reads into different
structural variants: original exon, replacement, insertion or del-
etion. Alignments were done with BBmap or MiniMap2 [57]
and visualizedwith IGV (Interactive Genome Viewer). Analysis




10(Github/pigX). Plottingwas done in Ror Pythonwith a number
of the plots included in the Jupyter Notebooks.
4.6. Uni-directional targeted sequencing sample
preparation
Wild-type and treated cells having had the POLB exon 5 tar-
geted showing 50% mCherry expression were used. Samples
were prepared either as described in LAM-HTGTS [37] begin-
ningwith 500 ng of gDNAor based on the Tn5-Uditas protocol
[36] beginning with 50 ng gDNA. LAM-HTGTS was done
generally as published with a few modifications. A single bio-
tinylated gene-specific primer was used to amplify 500 ng
sonicated gDNA (1 kb peak) 80× rounds. Streptavidin Dyna-
beads were found to inhibit PCR so the concentration was
reduced to 1/10th and used to capture the amplified sequence.
Capture bead-DNAwaswashed and then the universal primer
was ligated on the end. This adapter-ligated sequencewas PCR
amplified with a universal primer and a nested gene-specific
primer 30×. We added Nextera adapters by 10× rounds
of amplification. Gel extract 300–500 bp smear 300–500 bp,
quantified by Qubit and Bioanalyzer, then sequenced with
Illumina MiniSeq. For Tn5 sample preparation, we modified
the UDiTaS protocol, 50 ng gDNA was washed 2× with SPRI
beads. Tagmentation used hyperactive Tn5 produced by the
Max Delbrueck Center protein production facility following
published protocols [58]. Samples were tagmented to add the
universal primer binding site. Sample was amplified with
gene-specific primer and universal primer 15×. A nested
primer with Illumina adapter sequences was added and
followed by PCR 15×. Then Illumina adapters were added
with 10× PCR. Amplicons 300–500 bp were gel extracted,
quantified by Qubit and Bioanalzyer, then sequenced with
Illumina MiniSeq.
4.7. Analysis of uni-directional targeted sequencing
All scripts and notebooks are on github.com/ericdanner/
REPlacE_Analysis. The analysis of the linear amplifiedsequences was based on the Uditas software (https://github.
com/editasmedicine/uditas). De-multiplexed samples are
run through pipeline 1 or pipeline 2. Pipeline 1 generates
amplicons of the various expected outputs and does a global
alignment using Bowtie2 [59]. Reads that align well and
cover the ligated junctions are analysed for InDels. If the
samples were prepared with Tn5, they contained UMIs.
Unique UMIs are tallied and editing outcomes are quantified.
LAM samples do not contain UMIs. In Pipeline 2, the reads are
checked for correct on-target priming. The samples are then
trimmed using Cutadapt [60] up to the expected break site
leaving only the sequence downstream of the break site. This
sequence is aligned globally using Bowtie2 to an index file
containing hg38 and the targeting vector.Data accessibility. Sequencing data are available. Sequence Read Archive
(SRA) accession: PRJNA622521. Extended protocols are available:
https://www.protocols.io/researchers/eric-danner/publications.
Plasmids were submitted to Addgene: https://www.addgene.org/
Ralf_Kuehn (#149344–#149354) and a folder of annotated genebank
(.gb) files is added as electronic supplementary material, S1. All
code used is available on Github: https://github.com/ericdanner.
This includes scripts, Jupyter notebooks and Conda environments.
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